← Volver a la portada
Estados Unidos · Plataformas y datos · Yahoo Finance

Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

Publicado por Yahoo Finance · Estados Unidos hace 11 h
Evolus logo
Evolus logo · Yahoo Finance

Resumen detallado

Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of…

Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027.

At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagship Jeuveau wrinkle treatment by introducing hyaluronic acid fillers in the U.S. and Europe. The company expects international operations to account for 10% of revenue this year.

CFO Tatjana Mitchell said revenue grew 14% year over year through the third quarter while operating expenses declined slightly. Evolus reaffirmed its full-year revenue guidance of $330 million to $337 million, representing growth of 11% to 13%, and its forecast for adjusted EBITDA in the low- to mid-single digits as a percentage of revenue.

Moatazedi characterized the aesthetics market as healthy, estimating that the toxin market grew in the upper single digits in the third quarter. He said the filler market, which had faced weaker consumer sentiment and slowing demand, has stabilized and is roughly flat to slightly growing this year.

Consumers seeking a more natural appearance are using less filler per treatment than during the post-COVID boom, Moatazedi said. He estimated that patient volume in the filler market could be growing in the mid- to high-single digits even as unit volumes remain roughly flat.

He also said clinics are seeing patients who use GLP-1 drugs express concern about facial volume loss. Evolus has used the mention of GLP-1s in the Evolysse label in advertising developed with clinics, he said.

Moatazedi said more than 3,500 facilities have purchased Evolysse in the five quarters since launch, with reorder rates moving closer to Jeuveau levels. Evolysse is approaching a mid-single-digit market share, he said.

Evolus expects to launch Evolysse Sculpt in the first quarter of 2027, subject to approval, followed by a lip product in 2028.

Chief Medical Officer Rui Avelar said Sculpt is…

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar